ZYME
Zymeworks Inc
Price:  
12.96 
USD
Volume:  
309,636.00
Canada | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

ZYME WACC - Weighted Average Cost of Capital

The WACC of Zymeworks Inc (ZYME) is 10.3%.

The Cost of Equity of Zymeworks Inc (ZYME) is 10.35%.
The Cost of Debt of Zymeworks Inc (ZYME) is 5.00%.

Range Selected
Cost of equity 8.70% - 12.00% 10.35%
Tax rate 0.40% - 2.40% 1.40%
Cost of debt 5.00% - 5.00% 5.00%
WACC 8.7% - 12.0% 10.3%
WACC

ZYME WACC calculation

Category Low High
Long-term bond rate 3.9% 4.4%
Equity market risk premium 4.6% 5.6%
Adjusted beta 1.06 1.27
Additional risk adjustments 0.0% 0.5%
Cost of equity 8.70% 12.00%
Tax rate 0.40% 2.40%
Debt/Equity ratio 0 0
Cost of debt 5.00% 5.00%
After-tax WACC 8.7% 12.0%
Selected WACC 10.3%

ZYME's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for ZYME:

cost_of_equity (10.35%) = risk_free_rate (4.15%) + equity_risk_premium (5.10%) * adjusted_beta (1.06) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.